GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immix Biopharma Inc (NAS:IMMX) » Definitions » Property, Plant and Equipment

Immix Biopharma (Immix Biopharma) Property, Plant and Equipment : $1.41 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Immix Biopharma Property, Plant and Equipment?

Immix Biopharma's quarterly net PPE increased from Sep. 2023 ($0.04 Mil) to Dec. 2023 ($0.05 Mil) and increased from Dec. 2023 ($0.05 Mil) to Mar. 2024 ($1.41 Mil).

Immix Biopharma's annual net PPE declined from Dec. 2021 ($0.01 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.05 Mil).


Immix Biopharma Property, Plant and Equipment Historical Data

The historical data trend for Immix Biopharma's Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immix Biopharma Property, Plant and Equipment Chart

Immix Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Property, Plant and Equipment
0.01 0.01 0.01 - 0.05

Immix Biopharma Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.04 0.05 1.41

Immix Biopharma Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the companyFixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.


Immix Biopharma  (NAS:IMMX) Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Immix Biopharma Property, Plant and Equipment Related Terms

Thank you for viewing the detailed overview of Immix Biopharma's Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.


Immix Biopharma (Immix Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
11400 West Olympic Boulevard, Suite 200, Los Angeles, CA, USA, 90064
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. It has two business units ImmixBio and Nexcella.
Executives
Jason Hsu director 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Carey Ng director 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Helen C. Adams director 15378 AVENUE OF SCIENCE, STE 100, SAN DIEGO CA 92128
Melissa Jane Buchan director 1920 MAIN STREET, SUITE 500, IRVINE CA 92614
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
Yekaterina Chudnovsky director, 10 percent owner C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Ilya M Rachman director, officer: CEO and Chairman 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Gabriel S Morris director, officer: Chief Financial Officer 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Sean Senn 10 percent owner 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Vladimir P Torchilin officer: Scientific Co-Founder 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Graham Ross officer: CMO & Head of Clinical Dev. 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064

Immix Biopharma (Immix Biopharma) Headlines

From GuruFocus